Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 14
2023 29
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response.
Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. Sadrkhanloo M, et al. Among authors: salimimoghadam s. Pharmacol Res. 2022 Aug;182:106311. doi: 10.1016/j.phrs.2022.106311. Epub 2022 Jun 15. Pharmacol Res. 2022. PMID: 35716914 Review.
EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions.
Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, Kakavand A, Tavakolpournegari A, Saebfar H, Heidari H, Salimimoghadam S, Entezari M, Taheriazam A, Hushmandi K. Hashemi M, et al. Among authors: salimimoghadam s. Biomed Pharmacother. 2022 Nov;155:113774. doi: 10.1016/j.biopha.2022.113774. Epub 2022 Oct 3. Biomed Pharmacother. 2022. PMID: 36271556 Free article. Review.
Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy.
Hashemi M, Moosavi MS, Abed HM, Dehghani M, Aalipour M, Heydari EA, Behroozaghdam M, Entezari M, Salimimoghadam S, Gunduz ES, Taheriazam A, Mirzaei S, Samarghandian S. Hashemi M, et al. Among authors: salimimoghadam s. Pharmacol Res. 2022 Oct;184:106418. doi: 10.1016/j.phrs.2022.106418. Epub 2022 Aug 28. Pharmacol Res. 2022. PMID: 36038043 Review.
Targeting PI3K/Akt signaling in prostate cancer therapy.
Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S, Hejazi ES, Aboutalebi M, Gholamrezaie H, Saebfar H, Salimimoghadam S, Mirzaei S, Entezari M, Samarghandian S. Hashemi M, et al. Among authors: salimimoghadam s. J Cell Commun Signal. 2023 Sep;17(3):423-443. doi: 10.1007/s12079-022-00702-1. Epub 2022 Nov 11. J Cell Commun Signal. 2023. PMID: 36367667 Free PMC article. Review.
Non-coding RNA-based therapeutics in cancer therapy: An emphasis on Wnt/β-catenin control.
Taheriazam A, Bayanzadeh SD, Heydari Farahani M, Mojtabavi S, Zandieh MA, Gholami S, Heydargoy MH, Jamali Hondori M, Kangarloo Z, Behroozaghdam M, Khorrami R, Sheikh Beig Goharrizi MA, Salimimoghadam S, Rashidi M, Hushmandi K, Entezari M, Hashemi M. Taheriazam A, et al. Among authors: salimimoghadam s. Eur J Pharmacol. 2023 Jul 15;951:175781. doi: 10.1016/j.ejphar.2023.175781. Epub 2023 May 11. Eur J Pharmacol. 2023. PMID: 37179043 Review.
New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis.
Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Bahonar A, Nakhaee Z, Entezari M, Beig Goharrizi MAS, Salimimoghadam S, Ren J, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Tan SC, Hushmandi K. Sadrkhanloo M, et al. Among authors: salimimoghadam s. Pathol Res Pract. 2023 Nov;251:154902. doi: 10.1016/j.prp.2023.154902. Epub 2023 Oct 21. Pathol Res Pract. 2023. PMID: 37922723 Review.
PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S, Nikpanjeh N, Rezaee A, Gholami S, Hashemipour R, Biavarz N, Yousefi F, Tashakori A, Salmani F, Rajabi R, Khorrami R, Nabavi N, Ren J, Salimimoghadam S, Rashidi M, Zandieh MA, Hushmandi K, Wang Y. Rezaei S, et al. Among authors: salimimoghadam s. Eur J Pharmacol. 2023 Sep 15;955:175909. doi: 10.1016/j.ejphar.2023.175909. Epub 2023 Jul 23. Eur J Pharmacol. 2023. PMID: 37490949 Review.
Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy.
Zandieh MA, Farahani MH, Daryab M, Motahari A, Gholami S, Salmani F, Karimi F, Samaei SS, Rezaee A, Rahmanian P, Khorrami R, Salimimoghadam S, Nabavi N, Zou R, Sethi G, Rashidi M, Hushmandi K. Zandieh MA, et al. Among authors: salimimoghadam s. Biomed Pharmacother. 2023 Oct;166:115283. doi: 10.1016/j.biopha.2023.115283. Epub 2023 Aug 9. Biomed Pharmacother. 2023. PMID: 37567073 Free article. Review.
STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies.
Hashemi M, Abbaszadeh S, Rashidi M, Amini N, Talebi Anaraki K, Motahhary M, Khalilipouya E, Harif Nashtifani A, Shafiei S, Ramezani Farani M, Nabavi N, Salimimoghadam S, Aref AR, Raesi R, Taheriazam A, Entezari M, Zha W. Hashemi M, et al. Among authors: salimimoghadam s. Environ Res. 2023 Sep 15;233:116458. doi: 10.1016/j.envres.2023.116458. Epub 2023 Jun 20. Environ Res. 2023. PMID: 37348629 Review.
Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions.
Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, Ahmadi F, Salimimoghadam S, Aref AR, Zandieh MA, Entezari M, Taheriazam A, Hushmandi K. Hashemi M, et al. Among authors: salimimoghadam s. Biomed Pharmacother. 2023 Feb;158:114204. doi: 10.1016/j.biopha.2022.114204. Epub 2023 Jan 4. Biomed Pharmacother. 2023. PMID: 36916430 Free article. Review.
44 results